Bringing Evidence to the Point-of-Care in Chronic Obstructive Pulmonary Disease: The EAPOC-COPD System
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Changes in COPD pharmacotherapy at the provider level
研究概览
简要总结
This study evaluates the implementation and impact of the Evidence-at-the-Point-of-Care Chronic Obstructive Pulmonary Disease (EAPOC-COPD) system, a computerized clinical decision support system designed to improve the quality of COPD care delivered in community pharmacies. Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and healthcare utilization, and significant gaps persist in key evidence-based practices, including symptom and exacerbation risk assessment, appropriate pharmacotherapy, provision of COPD action plans, and referral for specialist care.
The EAPOC-COPD system builds on a previously validated asthma platform and provides pharmacists with guideline-based decision support through a structured patient questionnaire and point-of-care recommendations, including treatment optimization and generation of personalized action plans.
This study will be conducted across six community pharmacies implementing the EAPOC-COPD system as part of a quality improvement initiative. Using a quasi-experimental interrupted time series design, outcomes during a 12-month intervention period will be compared to a 12-month pre-intervention baseline period.
The study will evaluate both implementation outcomes (including system uptake, usability, feasibility, and acceptability among pharmacy teams and patients) and effectiveness outcomes. Effectiveness outcomes include improvements in guideline-based COPD care processes, such as rates of symptom and exacerbation risk assessment, optimization of pharmacotherapy, provision of COPD action plans, and appropriate referral for specialist care.
Results from this study will inform the scalability and broader implementation of pharmacy-based clinical decision support tools to enhance chronic disease management and support the expanding role of pharmacists in delivering evidence-based COPD care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Health Services Research
- 盲法
- None (Outcomes Assessor)
盲法说明
Blinding will not be possible for participating providers or patients, given the nature of the EAPOC-COPD intervention as a point-of-care clinical decision support system integrated into routine care workflows.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study will involve two groups of participants: pharmacy team members and adult patients with COPD who interact with the EAPOC-COPD system during pharmacy encounters.
- •Pharmacy team participants will include pharmacists, registered pharmacy technicians, pharmacy assistants, and students working at one of the six participating community pharmacies. Individuals will be eligible if they are employed at one of the participating sites, have used the EAPOC-COPD system during the study period, are able to provide informed consent, and are able to complete an electronic questionnaire in English. Individuals will be excluded if they have not used the system during the study period or decline to participate.
- •Patient participants will include adults aged 18 years or older who interact with the EAPOC-COPD system during routine pharmacy care. Eligible patients will be those identified by pharmacy staff as receiving COPD-related care and who complete the EAPOC-COPD patient questionnaire during their pharmacy encounter. Patients must have also indicated willingness to be contacted regarding research participation and be able to provide informed consent. Patients who are under 18 years of age, otherwise unable to provide informed consent, or who decline participation will be excluded.
排除标准
- •Unwilling to use EAPOC-COPD system
研究组 & 干预措施
EAPOC-COPD system
The EAPOC-COPD system consists of: 1) a smart phone / tablet app or PC-based questionnaire which collects information directly from patients upon prompting; and 2) a point-of-care CDSS that wirelessly receives and processes questionnaire data in order to produce a symptom severity/exacerbation risk assessment, medication change recommendation, and COPD action plan, all of which is made available to pharmacy providers electronically. Once approved (by pharmacists or through provider sign-back), the personalized COPD action plan is automatically populated within the patient app/portal, enabling anywhere/anytime access for patients. Patients are also provided with educational resources within their app/portal, designed to improve health literacy, inhaler technique, and adherence to their action plan.
干预措施: EAPOC-COPD (Behavioral)
结局指标
主要结局
Changes in COPD pharmacotherapy at the provider level
时间窗: As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56)
Defined by the proportion of patients whose COPD medications were escalated ("stepped-up" from short- to long-acting bronchodilator, single to dual, or dual to triple therapy), measured at the provider level
次要结局
- Provider changes in comprehensive symptom and exacerbation risk assessment(As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56))
- Provider changes in referral to pulmonary rehabilitation in appropriate patients(As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56))
- Provider changes in COPD action plan delivery(As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56))
- Provider changes in influenza vaccination rates(As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56))
- Provider changes in smoking cessation advice provision(As provider behaviour is what is being measured, the time frame will be from site/provider recruitment (week 1) until the end of the study period (week 56))
研究者
Andrew Kouri
Scientist and Staff physician
Women's College Hospital